Healthcare & Life Sciences
Guide Therapeutics
United States
series-c-plus
series-c-plus
Stage
1
Investors
About
Guide Therapeutics develops lipid nanoparticles using DNA barcoding technology to identify and screen particles that can deliver nucleic-acid therapies specifically to targeted tissues and organs.
Explore Guide Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.